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Menopausal Complaints Are Associated With
Cardiovascular Risk Factors
Gerrie-Cor M. Gast, Diederick E. Grobbee, Victor J.M. Pop, Jules J. Keyzer,
Colette J.M. Wijnands-van Gent, Göran N. Samsioe, Peter M. Nilsson, Yvonne T. van der Schouw
Abstract—It has been hypothesized that women with vasomotor symptoms differ from those without with respect to
cardiovascular risk factors or responses to exogenous hormone therapy. We studied whether the presence and extent of
menopausal complaints are associated with cardiovascular risk profile. Data were used from a population-based sample
of 5523 women, aged 46 to 57 years, enrolled between 1994 and 1995. Data on menopausal complaints and potential
confounders were collected by questionnaires. Total cholesterol, systolic and diastolic blood pressures, and body mass
index were measured. Linear and logistic regression analyses were used to analyze the data. Night sweats were reported
by 38% and flushing by 39% of women. After multivariate adjustment, women with complaints of flushing had a
0.27-mmol/L (95% CI: 0.15 to 0.39) higher cholesterol level, a 0.60-kg/m2 (95% CI: 0.35 to 0.84) higher BMI, a
1.59-mm Hg (95% CI: 0.52 to 2.67) higher systolic blood pressure, and a 1.09-mm Hg (95% CI: 0.48 to 1.69) higher
diastolic blood pressure compared with asymptomatic women. Flushing was also associated with hypercholesterolemia
(odds ratio: 1.52; 95% CI: 1.25 to 1.84) and hypertension (OR: 1.20; 95% CI: 1.07 to 1.34). Results were similar for
complaints of night sweating. The findings support the view that menopausal complaints are associated with a less
favorable cardiovascular risk profile. These findings substantiate the view that differences in the presence of menopausal
symptoms as a reason for using hormone therapy could explain discrepant findings between observational research and
trials. (Hypertension. 2008;51:1492-1498.)
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A number of observational studies demonstrated a protec-tive association between hormone therapy (HT) and
cardiovascular disease (CVD).1–3 Placebo-controlled, ran-
domized trials, however, could not confirm a cardioprotective
effect and showed no overall benefit of HT on the risk of
cardiovascular events.4,5
Many potential reasons have been proposed to explain this
apparent discrepancy between the observational studies and
the trials. An important difference is that, in the observational
studies, the most common reason to initiate HT was to relieve
menopausal complaints. In contrast, in the trials, women with
severe complaints were either excluded or composed only a
minority of the total randomized population. Results of a
recent subgroup analysis of the combined Women’s Health
Initiative trials showed that women who initiated HT closer to
menopause had a reduced coronary heart disease (CHD) risk
compared with the increase in CHD risk among women initiat-
ing HT more distant from menopause.6 Moreover, among
women 50 to 59 years old at enrollment in the Women’s Health
Initiative, end-of-trial coronary calcium scores were lower in
women assigned to estrogens than in those assigned to placebo.7
A younger age is likely to be accompanied by a higher frequency
of menopausal complaints.
We hypothesized previously that women with vasomotor
symptoms may differ from those without with respect to
cardiovascular risk factors or responses to exogenous HT.8
Indeed, women with menopausal complaints have a lower
level of plasma antioxidant activity and an increased cardio-
vascular reactivity to stressful situations.9 In addition, 2
studies demonstrated that hot flushes are associated with an
increased blood pressure.10,11 Moreover, a recent subgroup
analysis of the combined Women’s Health Initiative trials
showed that the higher risks of CHD in women more distant
from menopause appeared to be concentrated in the small
subset of women with moderate or severe vasomotor symp-
toms.6 We examined whether the presence of menopausal
complaints is associated with CVD risk profile in a large,
community-based sample of perimenopausal women.
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The Eindhoven Perimenopausal Osteoporosis Study is a large
screening program, established to assess determinants of low bone
mineral density in perimenopausal women. The screening of women
was carried out between September 1994 and September 1995. The
study protocol was approved by 2 institutional review boards, and all
of the women provided written informed consent. A detailed descrip-
tion of the study population has been published previously.12
The participants eligible for this study consisted of 6700 women,
born between 1938 and 1948, aged 46 to 57 years, who took part in
the first cross-sectional part of the study. We excluded 1052 women
who did not provide information on menopausal symptoms, leaving
5648 women. Another 9 women were excluded because their blood
pressure could not be measured, 22 women were excluded because
their body mass index (BMI) could not be calculated, and 94 women
were excluded because they reported a history of CHD before the
baseline measurements, resulting in 5523 women for the analysis. Of
the 5648 women for whom we had information concerning com-
plaints, total cholesterol had been measured in a random selected
subsample of 2068 women.
Menopausal Complaints
To assess the frequency of flushing, 3 questions were asked, 1 on the
number of days a participant experienced hot flushes in the previous
week; 1 on the average frequency of hot flushes at 1 day; and 1 on
the highest number of hot flushes at 1 day. Two questions were asked
to assess the frequency of night sweats, 1 on the number of nights a
participant wakes up in the previous week because of night sweating
and 1 on the frequency of waking up per night because of night
sweating. From these questions, a dichotomous variable was created
for the absence or presence of flushing or night sweats.
Flushing or night sweating was present if a woman reported to
have 0 complaints during the previous week or if they answered
“yes” on 1 of the questions. In addition, 4 categories of flushing were
constructed: absent; having flushes for 5 days per week, with an
average of 4 a day, with the highest amount of flushes at 1 day
being 6 (low); having flushes for 2 to 7 days per week, with an
average of 6 or less a day, and the highest amount of flushes per day
being 12 (moderate); and having flushes for 5 days a week, with
an average of 3 to 7 a day, with the highest amount of flushes at 1
day being 4 to 30 (high). Moreover, 4 categories of night sweat
frequency were constructed: absent; having night sweats for 1 night
per week and being awake once (low); having night sweats for more
nights per week, but being awake once a night (moderate); and
having night sweats for more nights per week and also being awake
more than once a night (high).
Cardiovascular Risk Factors
The cardiovascular risk factors examined in the present study were as
follows: (1) total cholesterol levels, (2) hypercholesterolemia, (3)
systolic and diastolic blood pressure, (4) hypertension, and (5) BMI.
Nonfasting blood samples were taken, and total cholesterol levels
were assessed by using an automatic enzymatic procedure13 at the
laboratory of the Diagnostic Center Eindhoven. Hypercholesterol-
emia was defined as a total cholesterol level 6.5 mmol/L and/or the
usage of lipid-lowering drugs.14 Furthermore, systolic and diastolic
blood pressures were measured in a standardized manner using a
mercury manometer. One measurement was taken after the partici-
pant had been seated quietly in a comfortable posture, with feet flat
on the floor, with the back supported and the arm supported at or as
close to the level of the heart as possible. Hypertension was
classified as a systolic blood pressure 140 mm Hg, and/or a
diastolic blood pressure 90 mm Hg, and/or the usage of 1
antihypertensive drug. Weight and height were measured, and BMI
was calculated as weight in kilograms divided by height in meters
squared.
Confounders
Women completed questionnaires on education, pregnancies, total
duration of oral contraceptive use and HT, drinking of alcohol,
smoking behavior, and sport habits. In addition, information was
obtained about the use of antihypertensive and cholesterol-lowering
therapy (yes or no). Sports activities were classified as yes or no.
Smoking was categorized as never, past, or current smoking, and HT
use was categorized as current, yes but 3 year ago, and never use.
The participants were asked about their education and whether
education had been completed. From this information, the highest
attained level of education was defined and classified into 4
categories: primary education; lower/intermediate general and lower
vocational education; higher general and intermediate vocational
education; and higher vocational education and university.15
Data Analysis
All of the statistical analyses were performed using SAS 9.1 (SAS
Institute, Inc). Characteristics of the study population are described
for all of the women and for women with and without complaints
separately by means and SDs for normally distributed continuous
variables and numbers and frequencies for categorical variables.
Linear regression analysis was used to analyze the association
between the independent variable complaints of flushing or night
sweating and the continuous dependent variables cholesterol, systol-
ic and diastolic blood pressure, and BMI. The linear regression
coefficients () are presented with 95% CIs. Univariate analysis
(model 1) was performed to identify the crude relation between
menopausal complaints and cardiovascular risk factors, using the
group of women with no complaints as the reference category. In
addition, 3 multivariate models were used: model 2, including age;
model 3, including smoking, education, sports activities, and HT use;
and model 4, incorporating model 3 and BMI.
Because women with menopausal complaints might visit their
physician more frequently, and, therefore, have a higher chance of
blood pressure being measured and high blood pressure being
detected, we repeated the blood pressure analyses in the subgroup of
women who did not use antihypertensive drugs. HT is very effective
in reducing the menopausal symptoms, and it is likely that women
with the worst symptoms would be prescribed HT. Thus, although
HT use is strongly linked to the presence of menopausal complaints,
the therapy does not cause flushing, but, rather, the opposite is true.
Therefore, HT use is a different potential confounding factor than
others. For this reason, we repeated all of the analyses in the
subgroup of women not using HT.
Logistic regression analysis was performed to examine the relation
between menopausal complaints and the presence of hypertension,
using the same potential confounders as in the linear regression
analyses. P values at 0.05 were considered statistically significant.
Results
In total, 50% reported no symptoms of flushing and night
sweats. Flushing only was reported by 12% and night sweats
only by 11% of all women, whereas 27% reported having
both symptoms. The presence of complaints of night sweating
was more common among women with complaints of flush-
ing. The mean age of the study group was 50.32.4 years
(range: 46.0 to 57.0 years) and was higher in women with
complaints. In addition, women with complaints were more
likely to be current smokers, current HT users, and to be
lower educated than asymptomatic women. In addition, these
women were less likely to exercise (Table 1).
Cholesterol
Women with complaints of flushing had a 0.39-mmol/L (95%
CI: 0.27 to 0.50) higher cholesterol level than women without
(model 1; Table 2). The difference remained after multivar-
iate adjustment (model 4; Table 2; 0.27 mmol/L; 95% CI:
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0.15 to 0.39). Findings were similar for complaints of night
sweating. A total of 765 women had hypercholesterolemia
(Table 1). After multivariate adjustment (model 4; Table 2),
complaints of flushing, as well as night sweating, were
associated with an increased prevalence of hypercholesterol-
emia (odds ratio [OR]: 1.52, 95% CI: 1.25 to 1.84; OR: 1.40,
95% CI: 1.16 to 1.69, respectively).
Blood Pressure
Adjusted for age (model 2; Table 2), women with complaints
of flushing had a 1.46-mm Hg (95% CI: 0.40 to 2.51) higher
systolic blood pressure and a 1.03-mm Hg (95% CI: 0.44 to
1.62) higher diastolic blood pressure compared with asymp-
tomatic women. The differences remained after multivariate
adjustment (model 3; Table 2; 1.59 mm Hg [95% CI: 0.52 to
2.67] for systolic blood pressure and 1.09 mm Hg [95% CI
0.48 to 1.69] for diastolic blood pressure). Inclusion of BMI
(model 4; Table 2) in the adjustments attenuated the differ-
ences between women with and without complaints but most
were still statistically significant (0.81 mm Hg [95% CI:
0.22 to 1.84] and 0.62 mm Hg [95% CI: 0.04 to 1.19],
respectively). In total, 2830 women were hypertensive (Table
1). After adjustment for confounders (model 3; Table 2), the
presence of flushing was positively associated with hyperten-
sion (OR: 1.20; 95% CI: 1.07 to 1.34). When finally adding
BMI to the model (model 4; Table 2), the associations were
attenuated but still in the same direction with an OR of 1.11
(95% CI: 0.99 to 1.25). In the subgroup of 5074 women who
did not use antihypertensive drugs, the associations were
somewhat attenuated but were all in the same direction and
for night sweats still statistically significant. Results were
similar for complaints of night sweating (Table 2).
Body Mass Index
In the crude analyses (model 1; Table 2) of flushing, women
with complaints had a 0.67-kg/m2 (95% CI: 0.43 to 0.91)
Table 1. Characteristics of the Study Population of 5523 Dutch Women According to the Presence of
Flushing
Characteristics All Women (N5523)
Presence of Flushing
Absent (N3362) Present (N2161)
Age, meanSD, y 50.22.4 49.92.3 50.82.4
BMI, meanSD, kg/m2 25.54.4 25.34.3 25.94.5
Systolic blood pressure, meanSD, mm Hg 133.219.4 132.218.9 134.720.1
Diastolic blood pressure, meanSD, mm Hg 83.910.8 83.410.7 84.810.9
Cholesterol, meanSD, mmol/L 6.21.4 6.01.3 6.41.4
Night sweating, % (n)
Absent 61.9 (3418) 82.1 (2759) 30.5 (659)
Present 38.1 (2105) 17.9 (603) 69.5 (1502)
Hypertension, % (n)
No 48.8 (2693) 53.7 (1805) 47.4 (1025)
Yes 51.2 (2830) 46.3 (1557) 52.6 (1136)
Hypercholesterolemia, % (n)
No 63.0 (1303) 67.9 (856) 55.3 (447)
Yes 37.0 (765) 32.1 (404) 44.7 (361)
Sports activities, % (n)
No 57.2 (3104) 56.0 (1860) 59.1 (1244)
Yes 42.8 (2319) 44.0 (1459) 40.9 (860)
Hormone therapy, % (n)
Never 77.2 (4224) 80.9 (2698) 71.5 (1526)
Past 3.2 (175) 2.3 (75) 4.7 (100)
Current 19.6 (1072) 16.9 (563) 32.8 (509)
Smoking status, % (n)
Never 33.8 (1810) 35.4 (1163) 31.3 (647)
Past 32.1 (1718) 32.9 (1080) 30.8 (638)
Current 34.1 (1826) 31.7 (1042) 37.9 (784)
Education completed, % (n)
Primary 13.7 (738) 11.5 (378) 17.3 (360)
Lower/intermediate general, lower vocational 60.1 (3236) 59.1 (1950) 61.7 (1286)
Higher general, intermediate vocational 13.5 (724) 14.4 (475) 11.9 (249)
Higher vocational, university 12.7 (686) 15.0 (495) 9.2 (191)
Percentages include column percentages.
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higher BMI compared with asymptomatic women. Including
age and other confounders (model 3; Table 2) in the regres-
sion model weakened the results, but women who reporting
flushing still had a 0.60-kg/m2 (95% CI: 0.35 to 0.84) higher
BMI. Again, these results were essentially the same for
complaints of night sweats (Table 2).
When restricting the analysis to women not using HT,
results were essentially similar in this group for all of the
outcomes studied, and formal testing using interaction terms was
not statistically significant (P values ranged from 0.16 to 0.93).
Discussion
Our data show that women with complaints of flushing or
night sweats have an unfavorable cardiovascular risk profile
compared with women without vasomotor complaints and
with increased cholesterol levels, systolic and diastolic blood
pressures, and BMI.
The main strengths of our study are its size and the
community-based sampling that improves generalizability of
the findings. A limitation is that menopausal symptoms
cannot be measured, and we had to rely on self-reported data
on complaints. However, assuming that misclassification is
nonselective if present, the true relation between vasomotor
symptoms and CVD risk profile may be even stronger. For
the definition of hypertension, we relied on only 1 blood
pressure measurement. Because it has been shown that blood
pressure most likely decreases with follow-up visits because
of regression to the mean, the prevalence of hypertension in
our study may be overestimated.16 Therefore, these findings
should be interpreted with caution. For the continuous mea-
sure, it is not as much of a problem. Furthermore, for the
analyses of blood pressure, we presented the data for all of the
women and additionally for women not treated for hyperten-
sion. There are pros and cons for both analyses. Restriction to
women without hypertension treatment results in exclusion of
women with the highest blood pressures, whereas including
them results in underestimation of the true blood pressure of
the treated women. The fact that the associations with
menopausal complaints in the untreated women are compa-
rable to those including the treated women suggests that
blood pressure misclassification in the treated women is not a
major issue. This might be because of suboptimal treatment.
Finally, the cross-sectional nature of our study makes it
difficult to draw conclusions regarding causal pathways.
From the onset of menopause women may experience
troubling symptoms that can include vasomotor complaints
(hot flushes and night sweats), vaginal dryness, depression,
irritability, sleep disturbances, and changes in libido. Evi-
dence from longitudinal studies showed that particularly
vasomotor symptoms and vaginal symptoms are causally
related to the menopausal transition.17,18 For the present
analyses, we focused on vasomotor symptoms, because data
suggest that vaginal and vasomotor symptoms are likely to
reflect different pathophysiological processes.19
The prevalence of HT use in our study was 20%, which
is lower compared with the prevalence in countries such as
the United States. The higher HT use in the United States
could be a consequence of the fact that, in this country, HT
was at least in the past more frequently prescribed for the
Table 2. Adjusted Estimates for the Relationship Between
Presence of Menopausal Complaints and Cardiovascular Risk
Factors in 5523 Dutch Women
Models Flushing Night Sweats
Cholesterol,  (95% CI), mmol/L
Model 1 Present* 0.39 (0.27 to 0.50) 0.32 (0.19 to 0.44)
Model 2 Present† 0.31 (0.19 to 0.43) 0.27 (0.15 to 0.39)
Model 3 Present‡ 0.29 (0.17 to 0.41) 0.26 (0.14 to 0.38)
Model 4 Present§ 0.27 (0.15 to 0.39) 0.25 (0.13 to 0.37)
Hypercholesterolemia, OR
(95% CI)
Model 1 Present* 1.71 (1.43 to 2.05) 1.48 (1.23 to 1.78)
Model 2 Present† 1.56 (1.30 to 1.88) 1.41 (1.17 to 1.70)
Model 3 Present‡ 1.55 (1.28 to 1.87) 1.41 (1.17 to 1.70)
Model 4 Present§ 1.52 (1.25 to 1.84) 1.40 (1.16 to 1.69)
Systolic blood pressure, 
(95% CI), mm Hg
Model 1 Present* 2.49 (1.45 to 3.54) 2.02 (0.97 to 3.07)
Model 2 Present† 1.46 (0.40 to 2.51) 1.48 (0.43 to 2.52)
Model 3 Present‡ 1.59 (0.52 to 2.67) 1.80 (0.74 to 2.87)
Model 4 Present§ 0.81 (0.22 to 1.84) 1.13 (0.11 to 2.14)
Diastolic blood pressure, 
(95% CI), mm Hg
Model 1 Present* 1.37 (0.79 to 1.96) 1.10 (0.51 to 1.68)
Model 2 Present† 1.03 (0.44 to 1.62) 0.91 (0.32 to 1.50)
Model 3 Present‡ 1.09 (0.48 to 1.69) 1.05 (0.46 to 1.65)
Model 4 Present§ 0.62 (0.04 to 1.19) 0.65 (0.08 to 1.21)
Systolic blood pressure in
untreated women, 
(95% CI), mm Hg
Model 1 Present* 1.92 (0.87 to 2.97) 1.90 (0.85 to .96)
Model 2 Present† 0.90 (0.16 to 1.96) 1.40 (0.35 to 2.45)
Model 3 Present‡ 1.03 (0.05 to 2.11) 1.71 (0.64 to 2.77)
Model 4 Present§ 0.41 (0.63 to 1.45) 1.20 (0.17 to 2.23)
Diastolic blood pressure in
untreated women, 
(95% CI), mm Hg
Model 1 Present* 1.25 (0.66 to 1.84) 1.07 (0.47 to 1.67)
Model 2 Present† 0.91 (0.31 to 1.51) 0.90 (0.30 to 1.49)
Model 3 Present‡ 0.96 (0.35 to 1.58) 1.02 (0.42 to 1.63)
Model 4 Present§ 0.58 (0.01 to 1.16) 0.71 (0.13 to 1.29)
Hypertension, OR (95% CI)
Model 1 Present* 1.29 (1.15 to 1.43) 1.26 (1.13 to 1.41)
Model 2 Present† 1.17 (1.05 to 1.31) 1.20 (1.08 to 1.34)
Model 3 Present‡ 1.20 (1.07 to 1.34) 1.24 (1.10 to 1.38)
Model 4 Present§ 1.11 (0.99 to 1.25) 1.17 (1.04 to 1.31)
BMI,  (95% CI), kg/m2
Model 1 Present* 0.67 (0.43 to 0.91) 0.55 (0.31 to 0.79)
Model 2 Present† 0.62 (0.38 to 0.86) 0.51 (0.27 to 0.75)
Model 3 Present‡ 0.60 (0.35 to 0.84) 0.51 (0.28 to 0.75)
*Model 1 indicates univariate (crude) model.
†Model 2 is adjusted for age (continuous).
‡Model 3 is model 2 with smoking (never, past, or current), education
(primary, lower/intermediate general, lower vocational, higher general, inter-
mediate vocational, higher vocational, or university), sports activities (yes or
no), and hormone use (no; yes, but 3 years ago; or yes).
§Model 4 is model 3 with BMI (continuous).
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prevention of chronic diseases. In the Netherlands, however,
the main indication for HT use is the presence of menopausal
complaints and not preventive purposes.20 The latter is also
consistent with our findings that women with complaints
were more likely to be current HT users compared with
asymptomatic women.
In previous studies on HT, users tended to be more healthy
and health conscious than nonusers.21 This difference could
have led to an overestimation of the beneficial effects and an
underestimation of the risks associated with HT use. In our
cohort, however, we found that, compared with never users,
current users were more likely to be lower educated (72.6%
versus 78.1%, respectively) and to have hypertension (50.8%
versus 53.3%, respectively) and less likely to be a never-
smoker (35.1% versus 29.6%, respectively) and to exercise
(56.8% versus 58.4%, respectively). These findings support
the view that current users did not had a better cardiovascular
risk profile than the never-users and that the healthy user
effect probably does not hamper our results.
It is a matter of debate whether it is necessary to adjust for
BMI in the analyses regarding blood pressure. In our view,
BMI is an important determinant of blood pressure22,23 and is
causally related to endocrine and metabolic changes with
menopause, and factors in the causal pathway should not be
included in the regression models. The fact that adding BMI
to the model attenuated the results supports the view that BMI
lies in the causal pathway and that adjustment has led to an
overcorrection.
We dichotomized menopausal complaints. However, when
complaints of night sweats and flushing were categorized into
absent, low, moderate, and high frequency, mean cholesterol,
systolic and diastolic blood pressure, and BMI were signifi-
cantly higher with increasing frequency of complaints
(please see the data supplement available online at
http://hyper.ahajournals.org).
Although vaginal symptoms appear to be more closely
related to changes in androgens,24 vasomotor symptoms are
believed to be related to estrogen withdrawal that occurs with
the menopause. The latter is supported by the fact that HT is
the most successful therapy for reducing their occurrence.25
However, because there is no significant correlation between
plasma hormone levels and the occurrence of vasomotor
symptoms,26 estrogen withdrawal alone cannot fully explain
the cause of menopausal symptoms. A growing body of
evidence supports the hypothesis that hot flushes result from
a reduced thermoneutral zone.27 This reduction appears to be
closely related to increased central nervous levels of norepi-
nephrine (NE), partly through 2-adrenergic receptors.28 The
involvement of NE in central thermoregulation and the
etiology of hot flushes are supported by results from exper-
imental and animal studies that showed that increased central
nervous system levels of NE narrows the width of the
thermoneutral zone.29,30 This is consistent with results from
studies that showed that yohimbine, an 2-adrenergic antag-
onist, elevates brain NE31 and ultimately triggers hot flus-
hes.32 Thus, 2-adrenoceptors in the hypothalamus may be
responsible for the events of the hot flush.28 There is a line of
evidence that suggests that the dramatic estrogen variability
during the menopausal transition is involved in the etiology
of hot flushes.33,34 Because estrogens modulate the 2-
adrenergic receptors,35 it is possible that the fluctuations in
estrogen levels affect the 2-adrenergic receptors. A decline
in inhibitory presynaptic 2-receptors leads to increased NE
levels, which leads to inappropriate heat loss mechanisms and
an increased occurrence of hot flushes.28
The association of menopausal complaints with a more
adverse cardiovascular risk profile could result from a pri-
mary increase in sympathetic nervous system activity. It has
been observed that increased BMI36 and hypertension37 are
associated with an increased secretion of NE from sympa-
thetic nerves.38 Activation of the sympathetic nervous system
has also been shown to increase the production of serum
lipids and lipoproteins by altering lipid metabolic processes,39
although some studies have found no consistent effect.40,41
These findings warrant further investigation.
For the present study, we have studied the effects of BMI,
lipids, and blood pressure. It has to be acknowledged,
however, that time windows of exposure and outcome may
vary markedly for different cardiovascular risk factors. BMI
and lipids, for instance, most likely reflect effects that have
operated over longer periods of time. Blood pressure, how-
ever, is a measure that reacts to impulses much quicker. This
could be reflected in our findings, because cholesterol and
BMI showed the most marked differences, whereas the
findings for blood pressure were weaker. It would be inter-
esting to replicate and extend these findings in studies in
which other markers of CVD risk are used, such as lipopro-
tein subfractions, inflammatory markers, etc, and in which
CHD events are the outcome.
There are only a few known risk factors for menopausal hot
flushes. It has long been thought that women with a higher
body weight have a decreased risk for vasomotor symptoms
during menopause because of conversion of androgens to
estrogens in fat tissue.42,43 However, these studies are rela-
tively old,42,43 included very small sample sizes,43 and used
measures for fat mass that are currently considered less
appropriate (body weight or percentage ideal weight instead
of BMI or fat mass from dual energy x-ray absorptiometry
scanning).42 According to more recent investigations, includ-
ing our own, women with more body fat are more likely to
report hot flushes.44–46 An explanation might be that in-
creased body fat raises core body temperature,47 which
triggers hot flushes.
Our results show that the presence and frequency of
vasomotor menopausal complaints are associated with a more
harmful cardiovascular risk profile. These findings lend
support to our hypothesis that women with vasomotor symp-
toms differ from those without with respect to cardiovascular
risk factors. These findings substantiate the view that differ-
ences in the presence of menopausal symptoms as a reason
for using HT could explain discrepant findings between
observational research and trials.
Perspectives
It is beyond dispute that HT is the best remedy for meno-
pausal vasomotor symptoms.25 Hot flushes are likely to arise
as a result of a reduced thermoregulatory zone,27 which is
thought to be primarily caused by a heightened sympathetic
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nervous system.28–30 These alterations in the sympathetic
nervous system might be mediated by the estrogen with-
drawal associated with menopause.35 However, estrogen
levels stay low throughout menopause, and most hot flush
symptoms subside with time. Thus, although a decrease in
estrogen concentration could be the first change, it might not
directly cause symptoms.48 It may be speculated that estrogen
fluctuations, in addition to a low absolute estrogen levels, are
causing the symptoms.33,34 Moreover, supplementation of HT
might increase the absolute estrogen levels in such a way that
estrogen fluctuations are not powerful enough anymore to
cause symptoms. In the present study we found that vasomo-
tor symptoms are associated with an unfavorable cardiovas-
cular risk profile. Cardiovascular risk factors are also associ-
ated with an sympathetic nervous system activity.36 –39
Because a heightened sympathetic nervous system is thought
to be involved in the occurrence of menopausal symptoms, as
well as in the etiology of the cardiovascular risk profile, it is
plausible that the favorable effects of estrogens on the
cardiovascular system could derive from the inhibition of the
sympathetic nervous system.49,50 These findings should trig-
ger further research.
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